• Applied Workflows with 10 mM dNTP Mixture for DNA Synthesis

  2026-05-09

  The 10 mM dNTP (2'-deoxyribonucleoside-5'-triphosphate) Mixture empowers high-fidelity DNA synthesis, PCR, and advanced nanoparticle research with unparalleled stability and convenience. Discover optimized protocols, advanced troubleshooting, and the latest innovations for reproducible, efficient molecular biology workflows.

• 2X HyperFusion High-Fidelity Master Mix: Precision for Cloni

  2026-05-08

  Harness the power of 2X HyperFusion™ High-Fidelity Master Mix for high-accuracy DNA amplification and seamless blunt-end PCR product generation. Discover advanced workflows and troubleshooting strategies that accelerate cloning, CRISPR, and translational immunotherapy research.

• Berberine Hydrochloride Induces Tuft Cells to Prevent Bone L

  2026-05-08

  A recent study reveals that berberine hydrochloride mitigates estrogen deficiency-associated bone loss by expanding intestinal tuft cells through a butyrate-GPR41 signaling pathway. This mechanistic insight advances our understanding of the gut-bone axis, suggesting new approaches for postmenopausal osteoporosis and osteoimmune research.

• HotStart™ 2X Green qPCR Master Mix: Specificity & Real-Time

  2026-05-07

  HotStart™ 2X Green qPCR Master Mix enables high-sensitivity, SYBR Green-based real-time PCR with robust specificity and reproducibility. Antibody-mediated hot-start inhibition of Taq polymerase minimizes non-specific amplification, supporting precise nucleic acid quantification in gene expression studies.

• CP-673451: Selective PDGFRα/β Inhibitor for Tumor Models

  2026-05-07

  CP-673451 delivers exceptional selectivity for PDGFRα/β, enabling precise angiogenesis inhibition and tumor growth suppression in advanced xenograft models. Recent insights underscore its unique potency in ATRX-deficient glioma research, providing translational relevance for cancer biology workflows.

• Cimetidine: Advanced Histamine-2 Receptor Antagonist for Bar

  2026-05-06

  Cimetidine’s unique profile as a histamine-2 receptor antagonist and partial agonist empowers reproducible, high-throughput workflows in both gastrointestinal cancer and blood-brain barrier (BBB) research. Its superior solubility and validated purity, supplied by APExBIO, streamline experimental setup and troubleshooting for robust, data-driven outcomes.

• WNT5a/GSK3/β-Catenin Axis Controls FAP Adipogenesis in Muscl

  2026-05-06

  This study reveals that the WNT5a/GSK3/β-catenin signaling axis critically modulates adipogenic differentiation in skeletal muscle fibro/adipogenic progenitors (FAPs). The findings highlight potential intervention points for limiting muscle fatty degeneration, with direct implications for myopathy research and the development of targeted Wnt signaling pathway inhibitors.

• Integrated Gastric Cancer Assembloids: Modeling Tumor-Stroma

  2026-05-05

  This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids with distinct stromal subpopulations, closely mimicking the primary tumor microenvironment. The approach enhances the physiological relevance of preclinical drug testing and provides new insights into resistance mechanisms, with significant implications for personalized oncology.

• GSK343: Precision EZH2 Inhibitor Workflows in Epigenetic Can

  2026-05-05

  GSK343 is a benchmark EZH2 inhibitor for dissecting PRC2-driven gene silencing and histone H3K27 trimethylation. This guide delivers advanced workflows, troubleshooting solutions, and actionable insights for maximizing GSK343’s impact in epigenetic cancer research.

• Methyl-β-cyclodextrin: Technical Protocols for Membrane Rese

  2026-05-04

  Methyl-β-cyclodextrin (SKU C6939) is used for selective extraction of cholesterol and related lipids from biological membranes, enabling precise studies of membrane fluidity and lipid raft organization. This reagent is not suitable for diagnostic or therapeutic use, and its effectiveness depends on strict adherence to solubilization, storage, and workflow guidelines.

• TaqI Restriction Endonuclease: Fast, Specific DNA Digestion

  2026-05-04

  TaqI Restriction Endonuclease (SKU K3053) enables rapid, sequence-specific cleavage of plasmid, PCR, or genomic DNA, streamlining workflows that require quick and reliable DNA fragment generation. Optimized for speed and reproducibility, it excels in applications such as cloning where sticky end production and precise fragment sizing are essential. This enzyme is not suitable for diagnostic or therapeutic applications.

• Biomimetic Microparticles Disrupt Tumor pH for Chemo-Immunot

  2026-05-03

  This study introduces a biomimetic microparticle system capable of simultaneously disrupting the intracellular and extracellular pH homeostasis of tumor cells by co-delivering syrosingopine and a doxorubicin prodrug. The approach synergistically enhances chemotherapeutic and immunotherapeutic efficacy by targeting tumor metabolic adaptation and immune suppression, offering a new paradigm for tumor microenvironment modulation.

• CDK9 Inhibitor (A3294): Technical Use and Best Practices

  2026-05-02

  CDK9 inhibitor (A3294) enables selective, non-cytotoxic inhibition of cyclin dependent kinase 9 for research focused on transcription elongation and HIV-1 propagation. It is not suited for experiments requiring broad-spectrum CDK inhibition or for protocols needing long-term storage of working solutions.

• Ridaforolimus for Cancer & Senescence: Applied Protocols & T

  2026-05-01

  Ridaforolimus (Deforolimus, MK-8669) is a nanomolar-potent, selective mTOR inhibitor with proven antiproliferative and anti-angiogenic activity across diverse cancer cell lines and senescence models. This guide delivers practical workflows, troubleshooting strategies, and evidence-based protocol parameters, empowering researchers to maximize reproducibility and biological insight using APExBIO’s trusted reagent.

• Redefining ERα Precision: PPT in Translational Oncology

  2026-05-01

  This thought-leadership piece explores how PPT (Propyl Pyrazole Triol), a potent and selective ERα agonist from APExBIO, is transforming translational research. By integrating mechanistic discoveries—such as the FOXM1–ERα ceRNA network in female lung adenocarcinoma—with actionable protocol guidance and a competitive ligand landscape, we offer researchers a roadmap for leveraging PPT in oncology and hormone receptor studies. This article advances beyond standard product literature, providing strategic insights for experimental design, biomarker exploration, and future clinical translation.

16208 records 1/1081 page Next 12345 下5页 Last page